港股異動丨藥明康德AH股齊漲 H股年內累漲近44%
藥明康德(2359.HK)午後一度漲4.14%至79.2港元,年內累漲近44%,跑贏大盤表現(同期恆指累漲約20%);藥明康德A股今日收漲5.65%報69.55元,A股市值逼近2000億元。藥明康德6月23日晚間公告,年內第二次股份回購方案已於6月20日全部實施完畢。此次回購金額約10億元,回購的股份1577.54萬股已於6月24日悉數註銷。6月24日晚,公司再發公告稱,2025年第一次股份回購將按計劃繼續推進。上述兩份回購方案相互獨立,這意味着2025年尚未過半,藥明康德已進行了兩輪10億級別的回購。此外,根據聯交所權益披露資料,藥明康德H股於6月24日獲Computershare Hong Kong Trustees Limited在場內以每股均價76.7033港元增持117.86萬股,涉資約9040.25萬港元。增持後,其持股比例由18.78%上升至19.08%。(格隆匯)



Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.